No, semaglutide does not increase UTI risk based on FDA prescribing information and clinical trials
Sections were dewaxed and stained with a rabbit polyclonal anti-FITC (711900, Thermo Fisher Scientific, 1/100) plus secondary Alexa Fluor 488 antibody (Life Technologies, 1/200), and guinea pig anti-human insulin (A0564, Dako, 1/1000) plus secondary Alexa Fluor 546 antibody (Life Technologies, 1/1000) prior to confocal imaging as above
S., Lefkowitz, R
Insurance appeals are commonand often successfulwhen supported with proper medical documentation
Combining these effects generously suggests 5-8 pounds of potential weight loss, assuming optimal doses and individual responsiveness
The Bottom Line The appeal of needle-free GLP-1 options is understandable, but the current evidence does not support sublingual semaglutide drops or weight loss patches as effective alternatives to proven treatments